Home
AltruBio, Inc.

AltruBio, Inc. Market Share Analysis for August 2026

Industry: N/A

Domainaltrubio.com

Year Founded2020

Employees51 - 200

Annual Revenue< $1M

AltruBio, Inc.

AltruBio, Inc. (including company regionals)

altrubio.com

See more website traffic and engagement information

Total visits to AltruBio, Inc.'s top domains

Understand AltruBio, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

altrubio.com480

See more with Sales Intelligence

Avg. visit duration in AltruBio, Inc.'s top domains

Analyze AltruBio, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

altrubio.com00:00:58

See more with Sales Intelligence

Avg. pageviews on AltruBio, Inc.'s top domains

See how AltruBio, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

altrubio.com2.41

See more with Sales Intelligence

AltruBio, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by AltruBio, Inc.

These are the website technologies, by industry, used by AltruBio, Inc. top domains

Payment & Currencies (8)

Cart Functionality

Advertising (6)

DoubleClick

Cryptocurrency (2)

Bitcoin Acceptance

eCommerce (2)

OpenCart

More Technologies

8

See all

News & Signals from AltruBio, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAltruBio Inc. receives financing of $225M in Series B.AltruBio secures up to $225M Series B financing.

NewsAltruBio Inc. launches patient in Phase 2 clinical program of ALTB-268.AltruBio announces enrollment of first patient in Phase 2 clinical program of ALTB-268 for the treatment of ulcerative colitis.

NewsAltruBio Inc. hired Jeroen Grasman as chief financial officer on Aug 9th '21.AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced the appointment of Jeroen Grasman as chief financial officer.